Gastric inhibitory polypeptide receptor agonist long acting II therapeutic (Eli Lilly and Company)

N/A

Report date: 2024/03/18 17:55:01

Base Information

Drug NameGastric inhibitory polypeptide receptor agonist long acting II therapeutic (Eli Lilly and Company)
Drug Alias NameGIPR Agonist Long Acting II (Eli Lilly and Company)
ClassificationBiologics
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsObesityDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A